DelveInsight's, "Non-Hodgkin Lymphoma Pipeline Insight 2024" report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Hodgkin Lymphoma Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Non-Hodgkin Lymphoma Pipeline. Dive into DelveInsight's comprehensive report today! @ Non-Hodgkin Lymphoma Pipeline Outlook
Key Takeaways from the Non-Hodgkin Lymphoma Pipeline Report*
Stay ahead with the most recent pipeline outlook for Non-Hodgkin Lymphoma. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Non-Hodgkin Lymphoma Treatment
Non-Hodgkin Lymphoma Emerging Drugs Profile*Mosunetuzumab:
Mosunetuzumab is an investigational, humanized, T-cell bispecific antibody designed to engage T cells and redirect their cytotoxic activity against malignant B cells. Mosunetuzumab simultaneously binds to CD3 epsilon (CD3e), a component of the T-cell receptor (TCR) complex, and to CD20, a B-cell surface protein expressed in a majority of B-cell malignancies.*Tisagenlecleucel:
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy that involves genetically modified autologous T cells isolated from each individual patient. The reprogramming of the patient's T cells uses a lentiviral vector to encode an anti-CD19 chimeric antigen receptor (CAR).*Capivasertib:
Capivasertib binds to and inhibits all AKT isoforms. Inhibition of AKT prevents the phosphorylation of AKT substrates that mediate cellular processes, such as cell division, apoptosis, and glucose and fatty acid metabolism. Currently, it is in Phase II stage of clinical trial evaluation to treat Non-Hodgkin Lymphoma.*BI-1206:
BI-1206 is a high-affinity monoclonal antibody that selectivity binds to Fc?RIIB (CD32B), the only inhibitory member of the Fc?R family. Fc?RIIB is overexpressed in several forms of NHL and overexpression has been associated with poor prognosis in difficult-to treat forms of NHL, such as mantle cell lymphoma. By blocking Fc?RIIB, BI-1206 is expected to recover and enhance the activity of rituximab or other anti-CD20 monoclonal antibodies in the treatment of these diseases. In
HMPL-760 is an investigational, highly selective, non-covalent, third-generation inhibitor of BTK, both wild-type and C481S mutant enzymes, with pre-clinical data suggesting high target specificity and higher potency versus first generation BTK inhibitors. BTK C481S mutation plays an important role in resistance to certain BTK inhibitors.
Explore groundbreaking therapies and clinical trials in the Non-Hodgkin Lymphoma Pipeline. Access DelveInsight's detailed report now! @ New Non-Hodgkin Lymphoma Drugs
Non-Hodgkin Lymphoma Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration*
Non-Hodgkin Lymphoma Products have been categorized under various Molecule types such as*Monoclonal Antibody *Peptides *Polymer *Small molecule *Gene therapy
Unveil the future of Non-Hodgkin Lymphoma Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Non-Hodgkin Lymphoma Market Drivers and Barriers
Scope of the Non-Hodgkin Lymphoma Pipeline Report*Coverage- Global *Non-Hodgkin Lymphoma Companies-
Get the latest on Non-Hodgkin Lymphoma Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Non-Hodgkin Lymphoma Companies, Key Products and Unmet Needs
Table of Content*Introduction *Executive Summary *Non-Hodgkin Lymphoma: Overview *Pipeline Therapeutics *Therapeutic Assessment *Non-Hodgkin Lymphoma - DelveInsight's Analytical Perspective *Late Stage Products (Phase III) *Tisagenlecleucel:
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company
Contact Person:
Email: ybhardwaj@delveinsight.com
Phone: +14699457679
Address:
City:
State:
Country:
Website: https://www.delveinsight.com/
Source: www.abnewswire.com
.
(C) 2024 M2 COMMUNICATIONS, source